Can a kidney with a Renal Cell Carcinoma (RCC) lesion be transplanted?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: September 2, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Transplantation of Kidneys with RCC Lesions

Donor kidneys with small RCC lesions may be transplanted if the tumor is small (<2-4 cm) and complete excision with clear margins is possible, following a case-by-case evaluation. 1, 2

Criteria for Transplanting Kidneys with RCC

Size and Characteristics

  • Small RCC lesions (<2-4 cm) may be acceptable for transplantation 2
  • Bosniak I cysts can be left in the donor kidney 1
  • Bosniak II cysts require thorough assessment for solid components, septations, and calcifications 1
  • High-grade Bosniak cysts (III or higher) or small (T1a) RCC may be acceptable on a case-by-case basis 1

Surgical Management

  • Complete excision with clear margins is mandatory before transplantation 2, 3
  • Back-table tumor excision is the standard approach for incidentally discovered small RCCs 4
  • Partial nephrectomy techniques should be used to preserve maximum renal function 2

Evidence Supporting This Approach

The OPTN Disease Transmission Advisory Committee reviewed 147 cases of donor kidneys with known or suspected RCC at the time of transplant and found:

  • 21 kidneys were transplanted after tumor excision
  • 47 contralateral kidneys were transplanted
  • 198 non-renal organs were transplanted
  • No cases of RCC transmission were documented in any of these recipients 3

Case reports further support this approach, showing successful outcomes with small, incidentally discovered RCCs that were completely excised before transplantation 5.

Risk Considerations

Transmission Risk

  • Cancer transmission from donors is rare (1-2 cases per 10,000 organ transplant recipients) 1
  • Transmission risk varies by cancer type, with in situ cancers having <0.1% risk 1
  • RCC transmission appears extremely low when proper selection criteria and surgical management are followed 3

Post-Transplant Monitoring

  • Regular imaging follow-up is recommended, though no cost-effective screening protocol has been established specifically for RCC after transplantation 2
  • The median time from transplantation to cancer diagnosis (for transmitted cancers) is approximately 8 months (IQR 3-13 months) 1

Decision-Making Process

  1. Evaluate tumor size (<2-4 cm is potentially acceptable)
  2. Confirm complete excision with clear margins is possible
  3. Assess tumor histology (favorable pathology is preferred)
  4. Consider the urgency of transplantation for the recipient
  5. Implement a shared decision-making approach with the recipient, providing clear information about the potential risks 1

Pitfalls to Avoid

  • Failing to thoroughly assess the tumor characteristics before transplantation
  • Incomplete excision of the tumor before transplantation
  • Inadequate follow-up imaging after transplantation
  • Not considering the risk-benefit ratio for individual recipients, particularly those with long waiting times on dialysis 1

This approach helps expand the donor pool while maintaining safety, as the risk of death while waiting for a kidney transplant may outweigh the minimal risk of tumor transmission when proper protocols are followed 1, 3.

References

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.